Said EM, Abdulaziz BA, Kassas ME, El Attar IH, et al. Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir the Arch Virol 2024;169:45.
PMID: 38349452